Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of Tuesday, October 6, 2026.
RETURN ON EQUITY (ROE)
N/A
Market Cap
$131.16M
Return on Equity (ROE)
-262.64%
TTM Avg
-45.72%
3Y Avg
-38.99%
5Y Avg
-37.83%
Market Cap
$131.55M
Return on Equity (ROE)
-266.86%
TTM Avg
156.76%
3Y Avg
98.17%
5Y Avg
-694.29%
Market Cap
$135.82M
Return on Equity (ROE)
-43.42%
TTM Avg
-36.99%
3Y Avg
-36.99%
5Y Avg
-36.99%
Market Cap
$136.58M
Return on Equity (ROE)
15.55%
TTM Avg
-9.97%
3Y Avg
-34.81%
5Y Avg
-26.89%
Market Cap
$130.16M
Return on Equity (ROE)
-11.20%
TTM Avg
-11.86%
3Y Avg
-12.45%
5Y Avg
-5.17%
Market Cap
$138.03M
Return on Equity (ROE)
-10.08%
TTM Avg
-25.77%
3Y Avg
-36.68%
5Y Avg
-27.09%
Market Cap
$138.54M
Return on Equity (ROE)
-44.26%
TTM Avg
-34.18%
3Y Avg
285.39%
5Y Avg
-5868.11%
Market Cap
$127.29M
Return on Equity (ROE)
N/A
TTM Avg
143.89%
3Y Avg
2.05%
5Y Avg
-53.47%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Freenome, Inc. (FRNM) | $133.18M | N/A | N/A | N/A | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $131.16M | -262.64% | -45.72% | -38.99% | -37.83% |
| LifeMD, Inc. (LFMD)vs › | $131.55M | -266.86% | 156.76% | 98.17% | -694.29% |
| Atrium Therapeutics, Inc. (RNA)vs › | $135.82M | -43.42% | -36.99% | -36.99% | -36.99% |
| Organigram Global Inc. (OGI)vs › | $136.58M | 15.55% | -9.97% | -34.81% | -26.89% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $130.16M | -11.20% | -11.86% | -12.45% | -5.17% |
| KORU Medical Systems, Inc. (KRMD)vs › | $138.03M | -10.08% | -25.77% | -36.68% | -27.09% |
| Alpha Cognition Inc (ACOG)vs › | $138.54M | -44.26% | -34.18% | 285.39% | -5868.11% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $127.29M | N/A | 143.89% | 2.05% | -53.47% |
| Pyxis Oncology, Inc. (PYXS)vs › | $127.21M | -775.59% | -106.56% | -86.72% | -48.99% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
